DE68914698D1 - Modifikation der Pharmakokinetika von Proteinen durch Ladungsänderung. - Google Patents

Modifikation der Pharmakokinetika von Proteinen durch Ladungsänderung.

Info

Publication number
DE68914698D1
DE68914698D1 DE68914698T DE68914698T DE68914698D1 DE 68914698 D1 DE68914698 D1 DE 68914698D1 DE 68914698 T DE68914698 T DE 68914698T DE 68914698 T DE68914698 T DE 68914698T DE 68914698 D1 DE68914698 D1 DE 68914698D1
Authority
DE
Germany
Prior art keywords
pharmacokinetics
proteins
charge
modification
changing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68914698T
Other languages
English (en)
Other versions
DE68914698T2 (de
Inventor
Alton C Morgan
Gowsala P Sivam
Paul G Abrams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poniard Pharmaceuticals Inc
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Application granted granted Critical
Publication of DE68914698D1 publication Critical patent/DE68914698D1/de
Publication of DE68914698T2 publication Critical patent/DE68914698T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
DE68914698T 1988-02-17 1989-02-17 Modifikation der Pharmakokinetika von Proteinen durch Ladungsänderung. Expired - Lifetime DE68914698T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/157,273 US5322678A (en) 1988-02-17 1988-02-17 Alteration of pharmacokinetics of proteins by charge modification

Publications (2)

Publication Number Publication Date
DE68914698D1 true DE68914698D1 (de) 1994-05-26
DE68914698T2 DE68914698T2 (de) 1994-08-25

Family

ID=22563038

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68914698T Expired - Lifetime DE68914698T2 (de) 1988-02-17 1989-02-17 Modifikation der Pharmakokinetika von Proteinen durch Ladungsänderung.

Country Status (5)

Country Link
US (1) US5322678A (de)
EP (1) EP0329185B1 (de)
JP (1) JPH0228200A (de)
AU (1) AU621342B2 (de)
DE (1) DE68914698T2 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0382781B1 (de) * 1987-10-23 1993-09-29 Genetics Institute, Inc. Zusammensetzung zur behandlung von krebs, gekennzeichnet durch überexpression des c-fms-proto-onkogens
US5635180A (en) * 1988-02-17 1997-06-03 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
ATE136224T1 (de) * 1989-09-29 1996-04-15 Neorx Corp Reduktion der nichtzielspezifischen retention von immunokonjugaten und ihren metaboliten
US5130129A (en) * 1990-03-06 1992-07-14 The Regents Of The University Of California Method for enhancing antibody transport through capillary barriers
US5105528A (en) * 1991-01-22 1992-04-21 Universal Instruments Corporation Method and apparatus for supplying and changing tips of a pick and place vacuum spindle
US5869457A (en) * 1991-03-11 1999-02-09 Rijksuniversiteit Te Groningen Modified proteins and their use for controlling viral infections
WO1994007138A1 (en) 1992-09-14 1994-03-31 Fodstad Oystein Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
NO180658C (no) 1994-03-10 1997-05-21 Oeystein Fodstad Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner
CA2190727C (en) * 1994-05-19 2006-07-18 Sudhakar Kasina Aromatic amine substituted bridged nitrogen and sulfur donor atom ligands for imaging
US5827498A (en) * 1994-06-07 1998-10-27 Nihon Medi-Physics Co., Ltd. Tumor affinity peptide, and radioactive diagnostic agent and radioactive therapeutic agent containing the peptide
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
GR1002903B (el) * 1995-11-21 1998-05-12 Antisoma Limited Πεπτιδιο συγγενες με ογκο και ραδιενεργος διαγνωστικος παραγοντας και ραδιενεργος θεραπευτικος παραγοντας που περιεχει το πεπτιδιο.
NO961031D0 (no) * 1996-03-13 1996-03-13 Det Norske Radiumshospital Tum Fremgangsmåte til å drepe uönskede målceller
US6271364B1 (en) 1999-02-23 2001-08-07 Amgen Inc. Analogs of NT-3
WO1998003546A1 (en) * 1996-07-19 1998-01-29 Amgen Inc. Analogs of cationic proteins
US6005083A (en) 1997-03-28 1999-12-21 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
WO1998056410A1 (en) * 1997-06-09 1998-12-17 Childrens Hospital Los Angeles Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence
US6991788B1 (en) 1997-06-09 2006-01-31 Childrens Hospital Los Angeles Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence
AU2002231621A1 (en) * 2000-11-09 2002-05-21 Immunolex Laboratories Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
EP1426382A1 (de) * 2002-12-06 2004-06-09 Aventis Behring GmbH Antivirales menschliches Serum Albumin
WO2005016260A2 (en) * 2003-08-08 2005-02-24 The Regents Of The University Of California Prodrugs for the oral and parenteral delivery of amine-containing drugs, amino acids, and peptides
CA2575784A1 (en) * 2004-08-03 2006-02-16 Becton, Dickinson And Company Use of magnetic material to fractionate samples
EP3050963B1 (de) * 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Verfahren zur herstellung von polypeptiden durch regulierung der anordnung
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
IN2014DN10515A (de) * 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
EP3345616A1 (de) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antikörpermodifizierungsverfahren zur reinigung von bispezifischem antikörper
EP2190861A4 (de) 2007-08-22 2011-03-30 Univ California Aktivierbare bindende polypeptide und verfahren zu deren identifikation und anwendung
CA2700701C (en) * 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
PL3059246T3 (pl) 2007-09-26 2018-11-30 Chugai Seiyaku Kabushiki Kaisha Zmodyfikowany region stały przeciwciała
EP2584043A3 (de) 2007-09-28 2013-10-02 Chugai Seiyaku Kabushiki Kaisha Anti-Glypican-3-Antikörper mit verbesserter Kinetik in Plasma
ES2834741T3 (es) * 2007-12-05 2021-06-18 Chugai Pharmaceutical Co Ltd Anticuerpo anti-NR10 y uso del mismo
US8937047B2 (en) * 2007-12-19 2015-01-20 General Electric Company Biokinetics of fast-clearing polypeptides
US8124725B2 (en) 2007-12-19 2012-02-28 General Electric Company PDGF-Rβ binders
SG189775A1 (en) 2008-04-11 2013-05-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
BRPI1006141B8 (pt) 2009-01-12 2021-05-25 Cytomx Therapeutics Llc composições de anticorpo modificado, métodos para preparar e usar as mesmas
JP5861223B2 (ja) 2009-02-23 2016-02-16 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. プロタンパク質およびその使用方法
TWI646193B (zh) 2009-03-19 2019-01-01 中外製藥股份有限公司 抗體恆定區域改變體
EP2409991B1 (de) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten antikörperregion
CN102459344A (zh) 2009-05-15 2012-05-16 中外制药株式会社 抗axl抗体
WO2011037158A1 (ja) 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
RU2012134366A (ru) * 2010-01-13 2014-02-20 ЭйПиТи ТЕРАПЬЮТИКС, ИНК. Терапевтические конструкции апиразы, средства на основе апиразы и способы получения
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
RS57038B1 (sr) 2010-11-17 2018-05-31 Chugai Pharmaceutical Co Ltd Multi-specifičan antigen-vezujući molekul koji ima alternativnu funkciju funkciji faktora viii koagulacije krvi
WO2012070964A1 (ru) * 2010-11-22 2012-05-31 Farber Boris Slavinovich Модифицированные олигопептиды с противораковыми свойствами и способ их получения
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
SG192945A1 (en) 2011-02-25 2013-09-30 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc antibody
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP3939996A1 (de) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur förderung der zersetzung von antigenen mit mehreren biologischen aktivitäten
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
SG10201803449VA (en) 2013-09-27 2018-05-30 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
CN105018442A (zh) * 2014-04-23 2015-11-04 Apt治疗公司 改进的en-腺苷三磷酸双磷酸酶
WO2015170480A1 (ja) 2014-05-08 2015-11-12 中外製薬株式会社 Ｇｐｃ３標的治療剤療法が有効である患者に投与されるｇｐｃ３標的治療剤
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CR20170326A (es) 2014-12-19 2017-08-22 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso
US9765135B2 (en) 2014-12-19 2017-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
WO2016136933A1 (ja) 2015-02-27 2016-09-01 中外製薬株式会社 Ｉｌ－６関連疾患治療用組成物
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JP7096667B2 (ja) 2015-07-01 2022-07-06 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
WO2017159287A1 (ja) 2016-03-14 2017-09-21 中外製薬株式会社 癌の治療に用いるための細胞傷害誘導治療剤
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
EP3620531A4 (de) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720765A (en) * 1970-10-27 1973-03-13 Monsanto Co Crosslinked protein with acid anhydride as a ruminant feed material
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2340911A1 (de) * 1973-08-13 1975-05-07 Behringwerke Ag Tetanus-antigen und verfahren zu seiner herstellung
US4118379A (en) * 1974-09-06 1978-10-03 Behringwerke Aktiengesellschaft Amidated immune globulins and process for preparing them
US4082507A (en) * 1976-05-10 1978-04-04 Sawyer Philip Nicholas Prosthesis and method for making the same
US4168262A (en) * 1978-03-13 1979-09-18 Cornell Research Foundation, Inc. Anhydride modified microbial protein having reduced nucleic acid levels
US4218539A (en) * 1978-03-24 1980-08-19 Weltman Joel K Enzyme conjugates and method of preparation and use
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4501692A (en) * 1979-07-26 1985-02-26 Syva Company Charge effects in enzyme immunoassays
US4414147A (en) * 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4749570A (en) * 1981-12-31 1988-06-07 The Governors Of The University Of Alberta Targeting conjugates of albumin and therapeutic agents
IT1150213B (it) * 1982-03-02 1986-12-10 Italfarmaco Spa Derivati di ferro biodisponibile esenti da gastrolesivita',procentimento di preparazione e relative composizioni farmaceutiche
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
ATE64396T1 (de) * 1983-04-29 1991-06-15 Omnichem Sa Konjugierte vinblastin-verbindungen und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4560504A (en) * 1984-12-06 1985-12-24 Uop Inc. Carboxyl anchored immobilized antibodies
US5045303A (en) * 1985-05-17 1991-09-03 Neorx Corporation Radiohalogenated small molecules for protein labeling
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5151266A (en) * 1985-08-20 1992-09-29 Neorx Corporation Use of anionic detergents with conjugates of monoclonal or polyclonal antibodies
CA1282069C (en) * 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
EP0268707A3 (de) * 1985-11-05 1989-03-08 The General Hospital Corporation Negativ geladene spezifische Affinitätsreagenzien
US5223242A (en) * 1985-11-05 1993-06-29 The General Hospital Corporation Negatively charged specific affinity reagents
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US4931544A (en) * 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
US5034223A (en) * 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5084556A (en) * 1987-10-23 1992-01-28 Genetics Institute, Inc. Composition of M-CSF conjugated to cytotoxic agents and a method for treating cancers characterized by over-expression of the c-fms proto-oncogene
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5089261A (en) * 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5162505A (en) * 1989-09-19 1992-11-10 Centocor Proteins modified with positively charged carriers and compositions prepared therefrom
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration

Also Published As

Publication number Publication date
DE68914698T2 (de) 1994-08-25
EP0329185A3 (en) 1990-05-16
JPH0228200A (ja) 1990-01-30
EP0329185A2 (de) 1989-08-23
AU3006989A (en) 1989-08-17
US5322678A (en) 1994-06-21
EP0329185B1 (de) 1994-04-20
AU621342B2 (en) 1992-03-12

Similar Documents

Publication Publication Date Title
DE68914698T2 (de) Modifikation der Pharmakokinetika von Proteinen durch Ladungsänderung.
DE69008891T2 (de) Lagerung von Materialien.
NO902038D0 (no) Bitumenpolymerblandinger.
NO864139D0 (no) Polypeptid virksomt ved dannelse av aids-antistoff.
DE3879452T2 (de) Chimaere antikoerper.
NO895010D0 (no) Konstruksjonsmateriale.
DE68904679T2 (de) Elektroplattierung von kleinen partikeln.
DE3877862T2 (de) Bestimmung der ausrichtung von bauteilen.
NO892294L (no) Polypeptidforbindelser.
DE68924246T2 (de) Tonerzusammensetzung.
DE68912109T2 (de) Justierung von quadratursignalen.
DE68924932D1 (de) Piezoelektrische Vibrator-Komponente.
NO890774D0 (no) Ekspresjon av hiv-bindende proteiner.
DE3863393D1 (de) Verbesserung der cetanzahl von dieselkraftstoffen.
NO892949D0 (no) Nye proteiner.
ATE125794T1 (de) Prodrogen von antiinflammatorischen 3-acyl-2- oxindol-1-carboxamiden.
DE69019244T2 (de) Ladungspumpe.
NO892948D0 (no) Modifiserte proteiner.
DE3881991D1 (de) Zusammensetzung von gleitgliedern.
DE69002136D1 (de) Saccharidderivate von protocatechualdehyd.
DE68912248D1 (de) Diuretischer Faktor.
DE68915248D1 (de) Unterscheidung von Bildbereichen.
DE3881393D1 (de) Dehydrobromierung von substituiertem alpha-halocumol.
NO874091D0 (no) Nye trombolytiske proteiner.
IT8705142A0 (it) Ponte anti-cariche elettrostatiche.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee